Citi analyst Yigal Nochomovitz lowered the firm’s price target on Biomea Fusion (BMEA) to $7 from $9 and keeps a Buy rating on the shares. The firm cites the recent share dilution for the target cut but sees a good setup for the stock into the company’s second half of 2025 updates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion price target lowered to $10 from $30 at Scotiabank
- Promising Developments in Biomea Fusion’s Metabolic Programs Justify Buy Rating
- Biomea Fusion Reports Q2 2025 Financial Results
- Biomea Fusion price target lowered to $9 from $10 at Oppenheimer
- Biomea Fusion files $300M mixed securities shelf